Shilpa Medicare launches bortezomib injection in US market

Shilpa Medicare today announced the launch of BORUZU™, (Bortezomib for injection 3.5mg/1.4ml), in the United States through its marketing partner, Amneal Pharmaceuticals. This new presentation of bortezomib is designed for ready-to-use subcutaneous or intravenous administration. According to the company, this ready-to-use oncology product reduces compounding preparation steps. Shilpa Medicare highlights that the product has already secured a permanent J-code from U.S. Centers for Medicare & Medicaid Services (CMS). Bortezomib injection is used for the treatment of multiple myeloma and mantle cell lymphoma. Shilpa Medicare developed the molecule, with Amneal set to handle manufacturing and commercialization. Vishnukant Bhutada, Managing Director of Shilpa Medicare, stated that this launch demonstrates the company’s commitment to providing pharmacy efficient solutions and improving healthcare requirements.